Penetration capacity of spermatozoa from patients with oligoasthenoteratozoospermia into bovine cervical mucus before and after therapy with kallikrein.
Due to the high degree of subjectivity involved in quantifying sperm motility by light microscopy, it appeared of interest to compare the results obtained with a bovine mucus penetration test (Penetrak) to those of routine laboratory measurement before and after therapy with kallikrein (600 U/day). The study included 45 patients with oligoasthenoteratozoospermia (OAT syndrome) in the absence of genitourinary pathology or abnormal serum hormone levels. Infertile partnership has lasted for a mean of 3.2 years. Analysis of spermiograms and the penetration test were performed before and after 3 months of treatment. Neither of these techniques revealed significant alteration after treatment, nor was there a demonstrable success during the observation period in terms of pregnancy. Judging from these results, (1) kallikrein has no effect in patients with OAT syndrome and (2) the penetration test provides no additional information on the biological quality of ejaculate.
Maier
U
U
Department of Urology, University of Vienna Medical School, Austria.
Eisenmenger
M
M
D000328:Adult; D000818:Animals; D002417:Cattle; D002582:Cervix Mucus / Q000502:physiology*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007610:Kallikreins / Q000494:pharmacology* / Q000627:therapeutic use*; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D009845:Oligospermia / Q000503:physiopathology*; D011863:Radioimmunoassay; D013081:Sperm Motility / Q000187:drug effects / Q000502:physiology; D013084:Sperm-Ovum Interactions / Q000187:drug effects / Q000502:physiology*; D013094:Spermatozoa / Q000187:drug effects / Q000502:physiology*; D013739:Testosterone / Q000097:blood
D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D007610:Kallikreins